240 related articles for article (PubMed ID: 31259621)
1. Crystallized phenol for sacral hidradenitis suppurativa.
Turan E; Dogru O; Kargin S; Kerimoglu RS; Nazik EE
J Dermatolog Treat; 2021 Mar; 32(2):193-196. PubMed ID: 31259621
[TBL] [Abstract][Full Text] [Related]
2. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
[TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
4. Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries.
Hayama K; Fujita H; Hashimoto T; Terui T;
J Dermatol; 2020 Jul; 47(7):743-748. PubMed ID: 32441411
[TBL] [Abstract][Full Text] [Related]
5. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
6. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE
Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351
[TBL] [Abstract][Full Text] [Related]
7. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa.
Hessam S; Scholl L; Sand M; Schmitz L; Reitenbach S; Bechara FG
JAMA Dermatol; 2018 Mar; 154(3):330-335. PubMed ID: 29417136
[TBL] [Abstract][Full Text] [Related]
8. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes.
van der Zee HH; Jemec GB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S23-6. PubMed ID: 26470610
[TBL] [Abstract][Full Text] [Related]
9. Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.
Kerdel FR; Azevedo FA; Kerdel Don C; Don FA; Fabbrocini G; Kerdel FA
J Drugs Dermatol; 2019 Feb; 18(2):170-176. PubMed ID: 30811140
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa.
Golbari NM; Porter ML; Kimball AB
J Am Acad Dermatol; 2019 Jan; 80(1):114-119. PubMed ID: 30003993
[TBL] [Abstract][Full Text] [Related]
11. Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort.
Bianchi L; Caposiena Caro RD; Ganzetti G; Molinelli E; Dini V; Oranges T; Romanelli M; Fabbrocini G; Monfrecola G; Napolitano M; Egan CG; Musumeci ML; Lacarrubba F; Micali G; Passoni E; Calzavara-Pinton PG; Venturini M; Zanca A; Offidani AM
Clin Exp Dermatol; 2019 Jul; 44(5):e177-e180. PubMed ID: 30593710
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
13. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
[TBL] [Abstract][Full Text] [Related]
14. Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease.
Fabbrocini G; Ruina G; Giovanardi G; Dini V; Raone B; Venturini M; Caposiena Caro RD; Veraldi S; Cannavò SP; Merlo G; Bertoldi AM; Fiorentini F; Molinelli E; Atzori L; Bongiorno MR; Lo Re M; Skroza N; Lasagni C; Franchi C; Ardigò M; Di Costanzo L; Stingeni L; Amerio P; Sanna F; Pescitelli L; Broganelli P; De Cupis C; Gualberti G; Saragaglia V; Argenziano G
Dermatology; 2022; 238(3):487-497. PubMed ID: 34474409
[TBL] [Abstract][Full Text] [Related]
15. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
[TBL] [Abstract][Full Text] [Related]
17. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.
Rondags A; van Straalen KR; van Hasselt JR; Janse IC; Ardon CB; Vossen ARJV; Prens EP; van der Zee HH; Horváth B
Br J Dermatol; 2019 May; 180(5):1214-1220. PubMed ID: 30512186
[TBL] [Abstract][Full Text] [Related]
18. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
[TBL] [Abstract][Full Text] [Related]
19. Hidradenitis suppurativa in surgeons' practice: Prevalence and treatment approach according to the Hurley stage in Latvia.
Balcere A; Upeniece I; Snipe K; Jezupovs A
Dermatol Ther; 2021 Jan; 34(1):e14687. PubMed ID: 33331018
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
